The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications

  title={The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications},
  author={Steven Moylan and Michael Maes and N. R. Wray and Michael Berk},
  journal={Molecular Psychiatry},
In some patients with major depressive disorder (MDD), individual illness characteristics appear consistent with those of a neuroprogressive illness. Features of neuroprogression include poorer symptomatic, treatment and functional outcomes in patients with earlier disease onset and increased number and length of depressive episodes. In such patients, longer and more frequent depressive episodes appear to increase vulnerability for further episodes, precipitating an accelerating and progressive… 
Neuroprogression: the hidden mechanism of depression
The interest of this work is to review the metabolic processes involved in the morphologic alteration in the limbic system reported in patients with MDD, as well as the neurologic bases of this complex pathology that include environmental stress, genetic vulnerability, alterations in the neurotransmission, and changes in the neuroplasticity, all of which today bring into limelight a mechanism of progressive neuronal damage.
Putative neuroprotective agents in neuropsychiatric disorders
Targeting the Glutamatergic System to Treat Major Depressive Disorder
Evidence that the glutamatergic system holds considerable promise for developing the next generation of novel and mechanistically distinct agents for the treatment of MDD is reviewed, particularly with regard to the N-methyl-D-aspartate (NMDA) antagonist ketamine as a ‘proof-of-concept’ agent.
A phase-specific neuroimmune model of clinical depression
Biological substrates underpinning diagnosis of major depression.
  • E. Sibille, B. French
  • Psychology, Biology
    The international journal of neuropsychopharmacology
  • 2013
Current limitations in depression research are discussed, concepts of gene-to-disease biological scales are reviewed, human post-mortem brain findings related to pyramidal neurons, γ-amino butyric acid neurons, astrocytes and oligodendro Cytes are summarized and a focus on local cell circuits may provide an appropriate integration point and a critical link between underlying molecular mechanisms and neural network dysfunction in major depression.
Cognitive dysfunction in depression - pathophysiology and novel targets.
It is found that reciprocal and overlapping biological pathways may contribute to cognitive dysfunction in MDD, including an hyperactive hypothalamic-pituitary-adrenal axis, an increase in oxidative and nitrosative stress, inflammation, mitochondrial dysfunction, increased apoptosis as well as a diminished neurotrophic support.
The neuroprogressive nature of major depressive disorder: evidence from an intrinsic connectome analysis
Initial evidence supporting that impairment of intrinsic functional connectivity across the course of depression is a progressive process is provided.
Stress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention
A targeted and complementary approach to boosting both psychological and physiological resilience simultaneously during the prodromal stage of mood disorder pathology has the greatest promise for optimizing the neurodevelopmental potential of those individuals at risk of disabling mood disorders.


The neurobiology of depression: inroads to treatment and new drug discovery.
Evidence from preclinical, epidemiologic, and clinical studies has converged to convincingly demonstrate that stressful or traumatic events occurring in early life significantly increase the risk for depression and other psychiatric illnesses in adulthood.
Mechanisms of Illness Progression in the Recurrent Affective Disorders
  • R. Post
  • Psychology, Medicine
    Neurotoxicity Research
  • 2010
This view of the sensitization and cross-sensitization among stressors, episodes, and abused substances should lead to a fundamental re-conceptualization of the recurrent affective disorders not as benign, isolated episodes of “mental” illness, but as severe, potentially progressive and lethal medical disorders of brain and body that deserve careful life-long monitoring and treatment.
Glucocorticoids, cytokines and brain abnormalities in depression
The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression
Screening for inflammatory and neurodegenerative processes in depression will allow to discover new I&ND biomarkers, both at the level of gene expression and the phenotype, and elucidate the underlying molecular I &ND pathways causing depression; identify new therapeutic targets in the I& ND pathways; develop new anti-I&ND drugs for these targets; and select existingAnti-I &ND drugs or substances that could augment the efficacy of antidepressants.
The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
The role of the melatonergic system in MDD is summarized, some data suggest that agomelatine has not only antidepressant effects but also anxiolytic effects, with a potential benefit both on anxiety symptoms associated with MDD and in the treatment of generalised anxiety disorder.
Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression
Beneficial effects of EPO on hippocampus-dependent memory function and on depression-relevant behavior are demonstrated, highlighting EPO as a candidate agent for future management of cognitive dysfunction and mood symptoms in depression.
Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways.
It is concluded that the activation of peripheral and / or central IO&NS pathways may explain the co-occurrence of depression with the above disorders and shows that depression belongs to the spectrum of inflammatory and degenerative disorders.